- Velpatasvir
-
- $0.00 / 100g
-
2026-05-13
- CAS:1377049-84-7
- Min. Order: 1g
- Purity: 98%-102%
- Supply Ability: 10 KGS
- Velpatasvir
-
- $0.00 / 1g
-
2026-05-13
- CAS:1377049-84-7
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Velpatasvir
-
- $30.00 / 5mg
-
2026-05-11
- CAS:1377049-84-7
- Min. Order:
- Purity: 99.91%
- Supply Ability: 10g
|
| | Velpatasvir Basic information |
| Product Name: | Velpatasvir | | Synonyms: | Velpatasvir;GS 5816;velpatasvir(GS-5816);methyl ((2s)-1-((2s,5s)-2-(9-(2-((2s,4s)-1-((2r)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-1,11-dihydroisochromeno(4',3':6,7)naphtho(1,2-d)imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;Velpatasvir API;Unifiram (DM-232);GS 5816;GS-5816;CS-2204 | | CAS: | 1377049-84-7 | | MF: | C49H54N8O8 | | MW: | 883 | | EINECS: | 1592732-453-0 | | Product Categories: | 1377049-84-7 | | Mol File: | 1377049-84-7.mol |  |
| | Velpatasvir Chemical Properties |
| Melting point | >170oC (dec.) | | density | 1.314±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (>25 mg/ml) | | form | solid | | pka | 10.75±0.46(Predicted) | | color | Pale yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. | | InChIKey | FHCUMDQMBHQXKK-CDIODLITSA-N | | SMILES | C(OC)(=O)N[C@H](C1=CC=CC=C1)C(N1C[C@@H](COC)C[C@H]1C1NC(C2=CC=C3C4C(OCC3=C2)=CC2=C3C(=CC=C2C=4)N=C([C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(OC)=O)C(C)C)N3)=CN=1)=O |
| | Velpatasvir Usage And Synthesis |
| Description | Velpatasvir (1377049-84-7) is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa and Vosevi, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV. It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2 | | Uses | Velpatasvir is a NS5A inhibitor in patients with hepatitis C (HCV) infection. | | Definition | ChEBI: Velpatasvir is a complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. It has a role as an antiviral drug and a hepatitis C virus nonstructural protein 5A inhibitor. It is an organic heteropentacyclic compound, a N-acylpyrrolidine, a L-valine derivative, a carbamate ester, a member of imidazoles, a ring assembly and an ether. | | Brand name | Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir) | | in vivo | Velpatasvir (10 mg/kg/d, p.o.) alone or in combination with Sofosbuvir (HY-15005) (20 mg/kg/d) inhibits liver fibrosis in the CCl4-induced non-HCV rat model[3].
| Animal Model: | CCl4-induced non-HCV rat model[3] | | Dosage: | 10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d) | | Administration: | p.o. | | Result: | Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues.
Inhibited hepatic stellate cells (HSCs).
|
| | References | [1] JOHN O. LINK . Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®[J]. Bioorganic & Medicinal Chemistry Letters, 2019, 29 16: Pages 2415-2427. DOI:10.1016/j.bmcl.2019.04.027
[2] ONAT KADIOGLU . Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning[J]. Computers in biology and medicine, 2021, 133: Article 104359. DOI:10.1016/j.compbiomed.2021.104359 |
| | Velpatasvir Preparation Products And Raw materials |
|